Immune modulatory effects of oncogenic KRAS in cancer.

Immune modulatory effects of oncogenic KRAS in cancer.
复制标题

DOI:
10.1038/s41467-020-19288-6
复制
发表时间:
2020-10-28
影响因子:
16.6
通讯作者:
Zeiser R
Zeiser R
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Hamarsheh S;Groß O;Brummer T;Zeiser R

文献摘要

参考文献

被引文献

相似文献

致癌性KRAS突变是人类癌症中最常见的突变,但最难靶向。虽然由致癌KRAS下游信号传导引起的持续增殖是致癌的主要驱动因素,但越来越多的证据表明,它还介导自分泌效应和与肿瘤微环境(TME)的串扰。在这里,我们讨论了最近的报告连接KRAS突变与肿瘤促进炎症和免疫调节引起的KRAS,导致免疫逃逸的TME。我们讨论了KRAS诱导的炎症和免疫调节的临床前工作的背景下,目前正在进行的临床试验,针对癌症实体携带KRAS突变和策略,以克服癌基因诱导的免疫系统的影响。致癌信号在历史上与持续的癌细胞内在增殖相关,然而其在促进肿瘤免疫耐受性中的作用也变得明显。在这里,Hamarsheh及其同事回顾并讨论了致癌KRAS免疫调节作用的临床前工作及其潜在的临床应用。
Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream signalling is a main driver of carcinogenesis, there is increasing evidence that it also mediates autocrine effects and crosstalk with the tumour microenvironment (TME). Here, we discuss recent reports connecting KRAS mutations with tumour-promoting inflammation and immune modulation caused by KRAS that leads to immune escape in the TME. We discuss the preclinical work on KRAS-induced inflammation and immune modulation in the context of currently ongoing clinical trials targeting cancer entities that carry KRAS mutations and strategies to overcome the oncogene-induced effects on the immune system. Oncogenic signalling has been historically associated with sustained cancer cell-intrinsic proliferation, however its role in promoting tumour immunoresistance has also become evident. Here, Hamarsheh and colleagues review and discuss the preclinical work on the immune modulatory effects of oncogenic KRAS and the potential clinical application.
DOI: 10.1084/jem.20161707
发表时间: 2017-06-05
期刊: The Journal of experimental medicine
影响因子: --
作者:
Daley D;Mani VR;Mohan N;Akkad N;Pandian GSDB;Savadkar S;Lee KB;Torres-Hernandez A;Aykut B;Diskin B;Wang W;Farooq MS;Mahmud AI;Werba G;Morales EJ;Lall S;Wadowski BJ;Rubin AG;Berman ME;Narayanan R;Hundeyin M;Miller G
通讯作者: Miller G
DOI: 10.1158/1078-0432.ccr-13-2200
发表时间: 2014-04-15
影响因子: 11.5
作者:
Angevin, Eric;Tabernero, Josep;Kurzrock, Razelle
通讯作者: Kurzrock, Razelle
DOI: 10.1038/ncomms7285
发表时间: 2015-03-03
影响因子: 16.6
作者:
Grabner, Beatrice;Schramek, Daniel;Mueller, Kristina M.;Moll, Herwig P.;Svinka, Jasmin;Hoffmann, Thomas;Bauer, Eva;Blaas, Leander;Hruschka, Natascha;Zboray, Katalin;Stiedl, Patricia;Nivarthi, Harini;Bogner, Edith;Gruber, Wolfgang;Mohr, Thomas;Zwick, Ralf Harun;Kenner, Lukas;Poli, Valeria;Aberger, Fritz;Stoiber, Dagmar;Egger, Gerda;Esterbauer, Harald;Zuber, Johannes;Moriggl, Richard;Eferl, Robert;Gyorffy, Balazs;Penninger, Josef M.;Popper, Helmut;Casanova, Emilio
通讯作者: Casanova, Emilio
DOI: 10.1158/1078-0432.ccr-16-2554
发表时间: 2017-06-15
影响因子: 11.5
作者:
Dong, Zhong-Yi;Zhong, Wen-Zhao;Wu, Yi-Long
通讯作者: Wu, Yi-Long
DOI: 10.1158/0008-5472.can-15-2840
发表时间: 2016-06-01
期刊: Cancer research
影响因子: 11.2
作者:
Caetano MS;Zhang H;Cumpian AM;Gong L;Unver N;Ostrin EJ;Daliri S;Chang SH;Ochoa CE;Hanash S;Behrens C;Wistuba II;Sternberg C;Kadara H;Ferreira CG;Watowich SS;Moghaddam SJ
通讯作者: Moghaddam SJ